로딩 중…
지수 로딩 중…
HEM Pharma Inc.
376270· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩33,600-0.15%
2026-09-18
Financials
Valuation Metrics
HEM Pharma Inc.'s Market Cap is ₩2426B. At end of 2025 it was ₩3310B. Ranked #756 of 2,421 in KR market (top 31%), #335 of 1,640 on KOSDAQ (top 20%), #82 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 35%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 242.56B KRW | KR#756/2,421 Sec#82/231 |
| Revenue | 16.14B KRW | KR#2,197/2,421 Sec#163/231 |
| Net Income | -20.74B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 56.79B KRW | KR#2,143/2,421 Sec#189/231 |
| Net Assets | 16.22B KRW | KR#2,330/2,421 Sec#220/231 |
| Employees | 86 | KR#1,757/2,421 Sec#140/231 |
| Value | ||
| P/B | 14.96x | KR#2,392/2,421 Sec#217/231 |
| P/S | 15.03x | KR#2,317/2,421 Sec#176/231 |
| FCF Yield | -7.46% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -127.88% | KR#2,364/2,421 Sec#221/231 |
| ROA | -36.53% | KR#2,339/2,421 Sec#208/231 |
| Op. Margin | -105.44% | KR#2,305/2,421 Sec#174/231 |
| Revenue Growth | 1.54% | KR#1,421/2,421 Sec#139/231 |
| Financial Health | ||
| Debt Ratio | 250.12% | KR#2,207/2,421 Sec#222/231 |
| Total Debt | 17.65B KRW | KR#1,422/2,421 Sec#115/231 |
| FCF | -18.10B KRW | KR#1,873/2,421 Sec#176/231 |
| Cash | 7.56B KRW | KR#1,842/2,421 Sec#163/231 |
| Current Ratio | 0.66x | KR#2,064/2,421 Sec#197/231 |
| Performance | ||
| 1Y Return | 36.31% | KR#334/2,421 Sec#18/231 |
| 1M Return | -16.21% | KR#2,261/2,421 Sec#195/231 |
| From 52W High | -65.54% | KR#2,053/2,421 Sec#169/231 |
| 1Y MDD | -64.26% | KR#1,713/2,421 Sec#144/231 |
| Trading | ||
| Volume | 6,917 shares | KR#2,039/2,421 Sec#195/231 |
| Trading Value | 233.8M KRW | KR#1,214/2,421 Sec#124/231 |
| Foreign Own. | 0.82% | KR#2,096/2,421 Sec#206/231 |
| Per Share | ||
| EPS | -2,873 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,247 KRW | KR#2,009/2,421 Sec#164/231 |
Company Info
동사는 2016년 물리·화학·생물학 연구개발업을 목적으로 설립되었으며, 2024년 11월 코스닥시장에 기술성장기업으로 상장함. 2025년 1분기 일본 도쿄에 해외법인 HEM Pharma Japan을 설립하였고, 4월 로그미를 인수하여 자회사로 편입함. 장내미생물 시뮬레이션 기술인 PMAS를 활용한 맞춤형 헬스케어 사업과 LBP 디스커버리 플랫폼 사업을 영위하는 글로벌 마이크로바이옴 전문 헬스케어 기업임. HEM파마는 2016년에 설립되었으며 경기도 수원시에 본사를 두고 있습니다.